SCHEMBL3044397

SCHEMBL3044397

c1ccc2c(c1)CC(NCc1ccc(-c3ccc4[nH]cnc4c3)cc1)C2

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.46
GRIN2B Q13224 4/20 0.45
FYN P06241 1/20 0.42
MEN1 O00255 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
PRMT5 O14744 2/20 0.38
HRH3 Q9Y5N1 1/20 0.38
SLC2A1 P11166 3/20 0.37
QPCT Q16769 1/20 0.37
DRD2 P14416 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35
OPRK1 P41145 1/20 0.35
SIGMAR1 Q99720 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3040301 0.91 GRIN2B (0.43) HDAC1GRIN2BFYNPRMT5DRD2
SCHEMBL13136969 0.91 QPCT (0.47) HDAC1GRIN2BFYNMEN1RAB9A
Trifluoroacetic Acid SCHEMBL3050323 0.90 SLC2A1 (0.51) HDAC1GRIN2BFYNMEN1RAB9A
Hydrochloric Acid SCHEMBL3034191 0.90 GRIN2B (0.42) HDAC1GRIN2BFYNMEN1RAB9A
SCHEMBL13137147 0.89 GRIN2B (0.39) HDAC1GRIN2BFYNMEN1RAB9A
SCHEMBL13137107 0.88 QPCT (0.39) HDAC1GRIN2BFYNHRH3QPCT
SCHEMBL13137106 0.88 QPCT (0.39) HDAC1GRIN2BFYNHRH3QPCT
Hydrochloric Acid SCHEMBL3159892 0.88 GRIN2B (0.38) HDAC1GRIN2BFYNMEN1RAB9A
SCHEMBL13137266 0.87 GRIN2B (0.40) HDAC1GRIN2BFYNPRMT5QPCT
Hydrochloric Acid SCHEMBL3040330 0.87 QPCT (0.39) HDAC1GRIN2BFYNMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222345-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION 2010-09-02 US claimed
US-20100222345-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION 2010-09-02 US disclosed
EP-2049481-A2 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SmithKline Beecham Corporation (US) 2009-04-22 EP disclosed
WO-2008021851-A2 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION (US) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222345-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS OPRL1, OPRM1, OPRK1 HDAC1 2221/4885GRIN2B 148/4885FYN 2222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.